APC opens new headquarters in Dublin, creating 100 jobs

APC Ltd chief executive Mark Barrett (left) with co-founder Brian Glennon (right).

Irish pharmaceutical research firm APC Ltd is set to hire 100 new staff at its newly opened 6,000 sqm research centre in Cherrywood Business Park, Co. Dublin.

Aside from being the company’s headquarters, the building will also serve as APC’s research facility for biopharmaceuticals in the processes of informatics and other advanced analytical means to help streamline the development of their medicines in various fields, including cancer and HIV.

APC was founded by Prof Brian Glennon and Dr Mark Barrett and is a spin-out from the department of chemical and bioprocess engineering at UCD. Established in 2011, the firm provides pharmaceutical processing technologies and customised solutions to companies.

Highlighting the risk that was involved in establishing the company in the midst of an economic recession, Dr Mark Barrett, APC’s chief executive, said: “Turning a wonder molecule into a mass-produced medicine presents serious scientific and technological challenges, even for some of the largest companies in the world. In our research, Brian and I saw an opportunity”.

“Our success has come from working with talented and creative engineers and scientists. We are looking to expand the team with today’s announcement of 100 highly-skilled research and development jobs across chemical engineering, sciences and analytics,” said Mr Barrett.

“We need people who enjoy the rewards of working in an environment that is driven by cutting-edge technology and science. In return, we will provide them with an opportunity to do something extraordinary: to help change patient outcomes for the better,” he added.

The group currently employs over 60 people at its offices in Cherrywood. Its clients include 8 of the top 10 pharmaceutical companies and five of the top 10 biotech firms in the world. 80% of its services are export-driven and the company aims to reach revenues of €50m by 2020.

APC is supported by Enterprise Ireland, which provided R&D funding for the company’s team development, technology and international market access.

Ireland is the largest net exporter of pharmaceuticals and APC’s expansion confirms Ireland's increasing competitiveness as a destination for pharmaceutical and biotech research and development.
Email Newsletter Software by Newsweaver